JCN Network  Jun 5  Comment 
TOKYO, Jun 5, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced the first results for metastatic endometrial carcinoma obtained from a Phase Ib/II study (Study 111) of its in-house developed multi-kinase inhibitor lenvatinib mesylate (product...
FiercePharma  Jun 4  Comment 
Bayer and its stalwart Nexavar have had the first-line liver cancer field to themselves for years. But Eisai is doing its best to change that.
JCN Network  May 31  Comment 
TOKYO, May 31, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into a new joint research agreement with the Broad Institute, a collaborative research institute which includes researchers from the Massachusetts...
GenEng News  May 30  Comment 
Charles River Laboratories said today it has agreed with Eisai to extend their 2-year collaboration focused on discovering new treatments for tropical and neurological diseases, the value of which was not disclosed. The companies will continue...
Benzinga  May 18  Comment 
Corium International (NASDAQ: CORI) shares have been white hot over the past 10 days, rising more than 30 percent since the company reported positive preliminary results in the clinical study of its Corplex Donepezil Alzheimer's Disease (AD)...
SeekingAlpha  May 11  Comment 
GenEng News  Apr 20  Comment 
Eisai subsidiary H3 Biomedicine said today it has extended its more than 2-year-old collaboration with Foundation Medicine to discover and develop precision medicines in oncology. The value of the expanded collaboration was not disclosed. ...
Motley Fool  Apr 10  Comment 
The company has selected a new CEO, and that CEO's track record is sparking optimism.
GenEng News  Apr 5  Comment 
Meiji Seika Pharma granted Eisai exclusive rights to commercialize the Parkinson’s disease drug, safinaminde, in Japan, South Korea, Taiwan, Brunei, Cambodia, Laos, Malaysia, and the Philippines. Meiji is developing the selective monoamine...
FierceBiotech  Mar 31  Comment 
Merck KGaA spinoff licenses IBD drug to Eisai joint venture nptaylor Fri, 03/31/2017 - 04:27

You may also be interested in articles related to Eisai Co. Ltd. (ESALY):


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki